Author Correction: High-dose nusinersen for spinal muscular atrophy: a phase 3 randomized trial

Le résumé fourni par la source

In the version of the article initially published, there were errors in the NfL data in Fig. 2 , Table 2 and Extended Data Fig. 4 . The original figures and table are available for comparison in the Supplementary information accompanying this amendment. In the Results, in the “Part B cohort with infantile-onset SMA: neurodegeneration” section, the text “…compared with the ENDEAR matched sham group (30% reduction)” has been corrected to “…compared with the ENDEAR matched sham group (32% reduction)”, and “nominally significant P = 0.0050” has been corrected to “nominally significant P = 0.0075”. In the “Part B cohort with later-onset SMA: neurodegeneration” section, the text “nominally significant P = 0.0495” has been corrected to “nominally significant P = 0.0047”. These corrections have been made to the HTML and PDF versions of the article.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.